HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Tuesday, 25 July 2017

MSc Economics and Health Economics dissertations……

….are about to start.  Topics include
  • Cost-effectiveness of remifentanil intravenously administered patient-controlled analgesia versus pethidine intramuscular injection for pain relief in labour. 
  • Cost-effectiveness of a telehealth app to improve access to specialist care for patients with motor neurone disease
  • Estimating regional differences in incidence of cancer stratified by tumour type and patient characteristics
  • Labour market over-education and cognitive decline specific to preclinical dementia
  • The effects of a partner's heavy drinking on an individual's wellbeing.
Image: Out Drinking by Chris RubberDragon

  • The impact of father's work place pressure on children's well-being: a case study in the UK
  • Public preferences on access to mental health treatment with regards to employment status

Monday, 24 July 2017

Outcome measurement job in HEDS

We are looking for someone with a relevant economics, psychological or psychometrics or background to work with leading researchers in the field of outcome measurement using a mixed methods approach. The role is based in the Health Economics and Decision Science (HEDS) Section of ScHARR and will involve methodological research funded from a variety of sources including Duchenne UK and the Health Foundation.

The role will involve varied tasks, including the management, undertaking and analysis of qualitative interviews with a sample of people with DMD, and data collection and psychometric analyses of a larger online and paper-based cross-sectional survey which assesses quality of life of people with DMD. More generally, you will be involved in reviewing, interviewing, conducting focus groups, managing data-collection in questionnaire surveys, and undertaking psychometric analyses of preference-based (also known as utility) measures of health and other outcomes.

The closing date is 23 August 2017.  Further details are available here.

Friday, 21 July 2017

June’s CEAs, systematic reviews and epidemiological models in LMICs

To help us keep on top of current research in low and middle-income countries, we are running a monthly search of research that is aligned to our core research interests.  It's a simple search strategy, with those published in April that are most aligned to our interests listed below.  The full list of articles is kept in our "Searches archive" in the right-hand column.
  • Campos NG, Mvundura M, Jeronimo J, Holme F, Vodicka E, Kim JJ. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. BMJ open. 2017;7(6):e015048.
  • Pecenka C, Parashar U, Tate JE, Khan JAM, Groman D, Chacko S, et al. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh. Vaccine. 2017;35(32):3982-7.
  • Sartori AMC, Rozman LM, Decimoni TC, Leandro R, Novaes HMD, de Soarez PC. A systematic review of health economic evaluations of vaccines in Brazil. Human vaccines & immunotherapeutics. 2017;13(6):1-12.
Image: The needle by Partha S. Sahana

Wednesday, 19 July 2017

June’s CEAs.....

Our quick search for CEA’s published in May uncovered 46 articles.   In the right-hand column of this blog is a CEA Archive, which includes our CEA search results by month.  Below are those in our areas of interest.
  • Hernaes UJV, Johansson KA, Ottersen T, Norheim OF. Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss. PharmacoEconomics. 2017.
  • Krog AH, Sahba M, Pettersen EM, Wisloff T, Sundhagen JO, Kazmi SS. Cost-utility analysis comparing laparoscopic vs open aortobifemoral bypass surgery. Vascular health and risk management. 2017;13:217-24.
  • Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporosis international 2017;28(6):1939-50.
  • Zhang S, Incardona B, Qazi SA, Stenberg K, Campbell H, Nair H. Cost-effectiveness analysis of revised WHO guidelines for management of childhood pneumonia in 74 Countdown countries. Journal of global health. 2017;7(1):010409.
Image: 46 by duncan c

Tuesday, 18 July 2017

Kadcyla ‘yes’ from NICE

From the NICE website:

“Kadcyla is currently being funded through the Cancer Drugs Fund (CDF). The new agreement means if there are no appeals against the new draft guidance, the drug will move out of the CDF into routine NHS funding later this summer. This will mean eligible patients will no longer have to apply for funding and the drug will be paid for in the normal way.

Alongside the offer from Roche to reduce the cost to the NHS, another important factor in the decision to recommend the drug was the committee’s agreement that it was appropriate to compare Kadcyla with Herceptin plus capecitabine. NICE had previously compared Kadcyla’s efficacy against a different combination of treatments.This change was made because Herceptin plus capecitabine is now considered standard treatment for people with advanced breast cancer.

Based on the clinical and cost effectiveness analysis using this comparator, incorporating the new commercial access agreement and applying end-of-life criteria, the drug now comes within the range considered to be a cost-effective use of NHS resources.”

The ERG report for this was produced by ScHARR-TAG, and more specifically, Hazel Squires, John Stevens and Helen Bell.

Image: Yes by Quinn Dombrowski

Monday, 17 July 2017

CLAHRC HEOM Newsletter

The Health Economics and Outcomes Measurement worksteam of the Yorkshire and Humberside CLAHRC has published its summer newsletter.  Together with an introduction from the Acting Theme Lead – Tracey Young – it provides news of recent fellowships, EQ-5D work and cost-effectiveness studies of population health checks and renal dialysis.

The newsletter is available here.

Image: Health by Got Credit

Saturday, 15 July 2017

HEDS in the media - April to June 2017

A lot of the research that ScHARR and HEDS conducts gains media and online attention. As per the last few quarterly periods we have taken a quick look at some the attention using Altmetrics to see what has been said about our work and how far and wide it has reached on social media channels.
Since the start of April till the end of June HEDS have been mentioned 759 times according to Altmetric data. Our research has been mentioned in 11 news stories, cited in two NICE policy documents (with eight combined citations), cited in Wikipedia four times and been subject to 687 Tweets.
Work on clinical effectiveness of bisphosphonates for the prevention of fragility fractures by HEDS was picked up for this article in The Conversation. It was then republished by CNN and then International Business Times and The World Economic Forum a couple of weeks later.
HEDS research was also cited in 12 blogs including The Mental Elf, The Academic Health Economist's Blog, Healthcare Economist and Latest BMJ Blogs. 
So far HEDS work has been Tweeted 7,775 times since Altmetric started collecting data
Image of world map of HEDS Tweets
Tweets by country

Thursday, 13 July 2017

New Technical Support Document

The latest TSD has been produced by the NICE DSU....

TSD19: Partitioned survival analysis for decision modelling in health care: A critical review.
It covers:
  • A description of the partitioned survival analysis approach and how it differs from more conventional state   transition   models   in   terms   of   structural   assumptions   and   data requirements
  • A  review  of  the  use  of  partitioned  survival  analysis in  recent  NICE TAs of  cancer treatments
  • A  critique  of  the  approach  focusing on the implications  of  the  structural  assumptions made for extrapolation and quantification of uncertainties
  • The   relative   merits of partitioned   survival   analysis and   state   transition modelling approaches
  • Recommendations  for  the  selection of  a  modelling  approach,  documentation  of  the selected approach, representation of uncertainties relating to extrapolation, and for further methods research
It is available here.

Wednesday, 12 July 2017

Consultation on NHS England Clinical Commissioning Policies

Even if you are not interested in the topics, they are worth looking at to see the complete contrast of methods used compared with NICE technology appraisals.  The following are open (for varying times)…
  • Mechanical thrombectomy for acute ischaemic stroke
  • Immediate Antiretroviral therapy for treatment of HIV-1 in adults and adolescents
  • Bendamustine with rituximab for first line treatment of mantle cell lymphoma
  • Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)

Monday, 10 July 2017

Health economics MSc Studentships available at Sheffield

Health economics is a growing area of applied economics where there is a national shortage of specialists, especially with good masters level qualifications.

There are studentships for MSc Economics and Health Economics at the University of Sheffield, funded by the National Institute for Health Research (NIHR).

These are for full time UK/EU students, covering a student stipend and fees, which are expected to be £14,553 and £6,500, respectively, for 2017-18,

Course can be found here.  Studentship details can be found here.

Image:learning by Allyssa Milan

For queries, contact the Course Director, Professor Aki Tsuchiya.  The closing date for studentship applications is Mon 7 August.